Novel technology has enabled researchers to better characterize pancreatic cancers at the molecular level. We wanted to explore some of the emerging discoveries, such as molecular subclassification, use of liquid biopsy and use of organoids in cancer assessment.
A literature review with a search specific to the topic, with recent reviews in major journals and a focus on the last 5 years (until December 2018), was done.
Pancreatic ductal adenocarcinoma (PDAC) may now be classified into clinical subgroups based on the predominant genomic profiles, but consensus on one classification system is lacking. Several subtypes have been suggested, including categories such as basal-like, stroma-activated, desmoplastic, pure classical and immune classical types. Further refinement may translate into clinically meaningful groups for therapeutic or prognostic purposes. Liquid biopsies (by means of circulating cancer cells, cell-free DNA, exosomes or other constituents of cancer cells in blood) may aid in earlier diagnosis, define prognostic groups and even predict therapy response and resistance. Organoids are increasingly used for the opportunity to investigate druggable and effective targets ex vivo and should facilitate personalized and precise, targeted therapy in the near future. While immunotherapy has not yet proved to be effective, a better understanding of molecular subgroups and specific immune profiles may help identify candidates for this approach in a more selective approach.
Novel molecular techniques have the potential to accelerate the road to improved outcomes in patients with pancreatic cancer.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Main novel aspects
Pancreatic cancer is increasingly understood at the molecular level, with attempts at subtyping groups with distinct outcomes and potential for therapeutic targets.
Liquid biopsies are investigated for their ability to monitor circulating biomarkers and thus potentially detect pancreatic ductal adenocarcinoma (PDAC) at an earlier stage when disease is resectable with the intent for cure, or to monitor the effect of surgery or chemotherapy over time.
Previous clinical trials for targeted therapy in PDAC have so far failed to show substantial survival benefits. Organoids are increasingly explored for the ability to test multiple drugs in vivo, in order to better target the druggable points in the individual patient’s cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal of all cancers with mortality almost equal to the incidence of the disease . PDAC is refractory to almost all current therapies. Despite being a devastating disease, only few major changes to its clinical management have been made over the past 50 years to improve prognosis, which remains extremely poor at present . Indeed, due to progress made in other cancer fields combined with an aging population, the predictions are that PDAC will become one of the leading causes of cancer-related deaths in the next decade .
One major factor contributing to the dismal prognosis is the late detection in the majority who present with the disease: more than half of patients present with distant metastases at the time of diagnosis; a further one third may have locally advanced or, at best, only borderline resectable disease—hence, usually less than 20% are amenable to surgical therapy, which is the only real chance of long-term cure. Data on the actual resection rates in population-based registries suggest there is huge variation in clinical practice . PDAC is notoriously resistant to most conventional chemotherapies, although some novel combinations have proven promising, such as FOLFIRINOX in the metastatic setting , for borderline disease , becoming the preferred standard in the adjuvant setting  and, furthermore, now investigated as an neoadjuvant approach to surgery in upfront resectable disease [8, 9]. Early diagnosis is hampered by the hard-to-access gland positioned in the posterior part of the abdomen. While novel technologies such as endoscopic ultrasound (EUS), computed tomography (CT) and magnetic resonance imaging (MRI) have made visualization of the gland more accurate , the criteria for selection of the population to be screened remains debatable . Pancreatic cancer is hereditary and associated with genetic syndromes in but a very small minority of cases [12‐14], and definite risk groups do not exist except for some cystic lesions  that are known to be premalignant or have malignant potential (Fig. 1). For the rest of the population, the risk factors are generic—smoking, obesity and aging are strongly related to risk of PDAC—and too general to allow for screening of particular persons at risk . Thus, great interest exists in investigating biological factors and novel technologies that can facilitate an earlier diagnosis or be predictive or prognostic for patients with PDAC. The aim of this narrative review is to give a brief insight into some of the molecular mechanisms and technologies that may improve diagnosis and therapy for PDAC in the near future.
This narrative review was based on a search of the PubMed database up to December 20, 2018, with a focus on articles written in the English language and published in the past 5 years on the topic of pancreatic cancer biology and novel methods for diagnosis and therapeutic targets.
Several steps towards increased understanding of pancreatic cancer have been made over the past decades . Pancreatic cancer most frequently arises from precursor lesions, named pancreatic intraepithelial neoplasia (PanIN) . Pancreatic cancer can also arise from larger precursor lesions such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms . A stepwise model  has been developed to understand the correlation between early morphological changes and associated genetic events , as depicted in Fig. 2. With the developments in sequencing technology, the next generation sequencing (NGS) platform has allowed for more widespread and complete characterization of the genomic landscape in PDAC. KRAS is the most consistently affected gene (>90% of tumours) harbouring oncogenic mutations at multiple hotspots, followed closely by CDKN2A, TP53, and SMAD4/DPC4 [20, 21]. The RAS-MAPK signalling pathway clearly plays a pivotal role in PDAC development, as up to 60% of the remaining KRAS wild-type tumours were shown to carry mutations in alternative members such as BRAF and ERBB2 .
The improved understanding gained from improved genome and transcriptome analyses has led to the characterization of molecular subtypes [22, 23]. The four subtypes, named “squamous”, “pancreatic progenitor”, “immunogenic”, and “aberrantly differentiated endocrine exocrine” (ADEX) correlate with histopathological characteristics and clinical outcomes (e. g. therapeutic response). The squamous tumours are enriched for TP53 and KDM6A mutations, show upregulation of the TP63N transcriptional network, and hypermethylation of pancreatic endodermal cell-fate determining genes. The squamous subclass of PDACs has a poor prognosis  and is predominantly associated with cancers of the pancreatic body and tail . Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (such as FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, as well as exocrine (NR5A2 and RBPJL) and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contain upregulated immune networks including pathways involved in acquired immune suppression. The four-tier classification scheme has recently been challenged, namely with a somewhat different yet overlapping system of five subtypes suggested, called “pure basal like”, “stroma activated”, “desmoplastic”, “pure classical” and “immune classical” . Subtyping of PDAC into meaningful clinical subgroups is likely to evolve as we learn more about the underlying molecular features and as technical sophistication evolves for further molecular investigation. At the moment, these molecular classifications are not in clinical use, but may aid in better substratification for improved understanding of the underlying biology and clinical behaviour of PDAC.
Also, while the turnaround time and costs of genetic testing have significantly decreased over the past decade, the practical application of molecular results to guide individual patient treatment is currently limited in PDAC. This is in part due to the presence of actionable targets in a relatively small proportion of patients, with studies reporting numbers as low as 26% of cases . On the other hand, the TGCA consortium has recently reported that up to 42% of patients carry at least one genetic alteration that could grant inclusion in ongoing clinical trials .
PDACs are known for their desmoplastic growth pattern, consisting of dense fibrotic reaction, inflammation and poor cellularity. In addition, the poor vessel density within the tumour partly explains both the hypoxic environment (lack of nutrients) and the poor response to most types of chemotherapy. The aggressive nature and early metastatic potential of PDAC sets in with an aggressive perineural growth pattern culminating by early invasion and metastasis, even when cancers are still considered small in size (<2 cm) [16, 27, 28]. Hence, PDACs have a bad biology even in the very early stages and for rather small tumours . Better and earlier detection is thus crucial for improved outcomes, as well as development of targeted drugs that have a higher efficacy to potentially increase the number of resectable cancers.
Outside specific genetic syndromes that have a defined risk for PDAC , there are no specific risk factors in clinical use for pancreatic cancer. Several techniques and novel diagnostic tools are explored for their ability to detect PDAC at an earlier, resectable and, still, curable stage in the general population. Several promising markers and tools have been proposed over the years, but the actual clinical impact has proven to be slow, with few if any available tests on the market. Many of the tests available take advantage of the deranged metabolism in PDAC, with changes in lipid and protein metabolism as well as development of hyperglycaemia and pre-diabetes in the years prior to detection of PDAC.
Among other tests available are endoscopic sampling and measurements of various biomarkers, ranging from proteins in blood or plasma and genetic mutations sampled in cyst fluid or from pancreatic juice  to a proposed “breath test” to measure volatile organic compounds in patients with PDAC . The interest in non-invasive tests stems from the difficult anatomical location of the pancreas, thus the development of a clinically available “liquid biopsy” is particularly of interest (Figs. 2 and 3). This utilises the exploration of circulating markers in blood, for which some promising technologies have recently made this come closer to clinical reality [32‐35].
Any bodily fluid can potentially be used for “liquid biopsy” sampling (e. g. urine, blood, spinal fluid etc), but peripheral blood is the most intensely investigated (Fig. 3a) as it contains circulating tumour cells (CTCs) and circulating tumour-derived cell-free DNA (ctDNA) that may project biological information of a cancer or precancer situation. Methods for enrichment and detection of CTCs and ctDNA, their clinical applications and future opportunities in gastrointestinal cancers are constantly developing, with refinement of technology and detection methods [34, 36]. PDAC is an interesting field for this technology as it may allow for non-invasive testing for an otherwise hardly accessible organ [34, 36‐40]. Reports on specific mutations or combinations of markers are promising [35, 37, 39, 41].
Biomarkers that can be detected in peripheral blood and predict the risk of having resectable cancer have become closer to reality with recent studies, such as that of CancerSEEK, showing promising results with clinical applications . Patients with positive CTCs prior to resection of PDAC have a poorer prognosis, even when adjusted for histologically unfavourable factors .
Traditional monolayer cell lines have proven useful in research in a variety of solid malignancies over the past decades. Nevertheless, these models carry numerous constraints, especially in poorly resectable, low-cellularity cancers such as PDAC, where the issue of representativity, both cellular (intratumoural sub-populations) and at the population level (interpatient tumour heterogeneity) plays a limiting role. Organoid culture methods have been recently established from clinical specimens [43‐47] and represent an incredible advantage over monolayer cell lines: they can be generated from a resected PDAC in about 2–4 weeks , are amenable to therapeutic screening as well as genetic and biochemical perturbation , and are able to recapitulate interactions between tumour and stromal compartment. Because organoids can be generated with high efficiency and speed from fine-needle aspirations, biopsies or resection specimens [43‐46], they can serve as a personal cancer model (Fig. 4). The biopsied or resected tumour tissue from the individual patient can be grown and tested for a plethora of potential drugs, only to choose the drug from samples that show any response in the organoid model. Hence, the efficacy may be increased by personalizing the type of therapy given to any patient with PDAC. Personalized treatment could soon become a more standard practice by using these cell cultures for extensive molecular diagnosis and drug screening [43, 47, 49]. Drug sensitivity assays can give a clinically actionable sensitivity profile of a patient’s cancer. Combined genomic, transcriptomic and therapeutic profiling of patient-derived organoids can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses and facilitate precision medicine for patients with PDAC .
Targeting specific mutations in pancreatic cancer has been a matter of research for over several decades now. The difficulties and obstacles that have been encountered during multiple therapeutic approaches to the RAS/RAF/MEK/ERK pathway are exemplarily on the so far fruitless way to an effective, personalized treatment . Although more than 90% of PDACs harbour a KRAS mutation, inhibition of RAS activation or its’ downstream signalling with farnesyltransferase inhibitors (tipifarnib), MEK 1/2 inhibitors (selumetinib, trametinib) alone or in combination with EGFR inhibitors (erlotinib) either did not show a significant benefit in survival or were not clinically applicant due to overlapping toxicities of small molecule inhibitors and necessary dose reductions. It has been shown that PDAC possess multiple resistance mechanisms to overcome selective signalling blockades induced by these drugs. Recently, a new strategy to control the “undruggable” KRAS oncogenic pathway has been postulated by inhibition of SIAH (seven in absentia homolog), the most downstream gatekeeper in this deleterious signalling cascade . However, pharmaceutical evaluation of this potential target is still pending to date.
According to a recent systematic review , an average yearly number of more than 60 clinical trials have been reported in the last years examining the efficacy of molecularly targeted therapies in unresectable PDAC, most commonly studying inhibitors of EGFR, VEGF, RAS pathways and tyrosine kinases. Especially EGFR inhibitors such as erlotinib, cetuximab and panitumumab have been extensively studied with phase I/II trials in this setting, albeit with limited numbers of patients and without a clear breakthrough in terms of overall or progression-free survival. Further results of phase III studies are therefore eagerly awaited.
As immune evasion is a well-described hallmark of cancer development, interest in targeting mechanisms that can trigger the immune system to attack cancer cells has gained increasing interest. Notably, immunotherapy has proved effective for some cancers, and changed the standard of care and life expectancy for several malignancies, such as cancers of the lung, head and neck, gastrointestinal tract, and for some colorectal cancers. Disappointingly, single-agent immunotherapy has had little effect in PDAC . Increasing evidence suggests that the PDAC microenvironment is comprised of an intricate network of signals between immune cells, PDAC cells and stroma, resulting in an immunosuppressive environment resistant to single-agent immunotherapies [54, 55]. It has also been shown that a higher density of CD3+ T‑cells in the stroma is associated with longer progression-free survival in patients with PDAC , and that combination of mutational profiles and immune markers may define subgroups of patients who may respond to specific types of therapies . These findings are promising and may represent potential paradigm changes in the approach to how individual patients with PDAC may be treated in the future.
Pancreatic adenocarcinoma (PDAC) is a lethal malignancy that is refractory to all current therapies. Research into the mechanisms driving this cancer is the key to developing better diagnostic and treatment options. PDAC may now be classified into clinical subgroups based on the predominant genomic profiles, but consensus on one classification system is still lacking. Both four and five subtypes have been suggested, including basal like, stroma activated, desmoplastic, pure classical and immune classical types. Further refinement may translate into clinical meaningful groups for therapeutic or prognostic purposes. Liquid biopsies (by means of circulating cancer cells, cell-free DNA, exosomes or other constituents of cancer cells in blood) may aid in earlier diagnosis, define prognostic groups and even predict therapy response and resistance. Organoids are increasingly evaluated for their ability to investigate druggable and effective targets in any individual patient and should facilitate personalized and precise, targeted therapy in the near future. Since most molecularly targeted therapies have not shown substantial benefit in clinical trials so far, some of the new molecular techniques raise hope of having the potential to accelerate improved outcomes in patients with pancreatic cancer.
Open access funding provided by University of Innsbruck and Medical University of Innsbruck
K. Søreide, F. Primavesi, K.J. Labori, M.M. Watson and S. Stättner declare that they have no competing interests.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.